文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

术后需重症监护的外科患者同期使用阿司匹林与抗凝治疗与主要出血风险增加相关

Concomitant Aspirin and Anticoagulation Is Associated With Increased Risk for Major Bleeding in Surgical Patients Requiring Postoperative Intensive Care.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论术后ICU抗凝的外科患者同期使用阿司匹林与主要出血风险增加相关(OR 1.20),近期新起始阿司匹林者关联更强(OR 1.40)。

该观察性队列研究在学术医疗中心术后ICU开展,纳入2007至2016年间术后ICU住院期间接受抗凝治疗的成人患者,比较同期使用阿司匹林与单用抗凝治疗的主要出血风险。采用逆概率治疗加权分析,同期治疗与主要出血风险增加相关(OR 1.20;95%CI 1.05-1.36;P=0.006)。交互检验提示阿司匹林与主要出血的关系因抗凝前7天内是否使用阿司匹林而异:近期新起始阿司匹林者关联强(OR 1.40;95%CI 1.13-1.72;P=0.002),而继续既往阿司匹林使用者未见此关联。抗凝前使用阿司匹林未改变同期治疗与新发心肌梗死或卒中的关系(即抗凝前停用阿司匹林未使这些事件率增加)。作者认为需进一步研究以明确外科患者抗凝期间抗血小板治疗的最佳管理。

要点

  • 术后ICU接受抗凝治疗的成人外科患者中,同期使用阿司匹林与主要出血风险增加相关(OR 1.20;95%CI 1.05-1.36;P=0.006)。
  • 近期新起始阿司匹林(抗凝前7天内)者与主要出血的关联更强(OR 1.40;95%CI 1.13-1.72;P=0.002),继续既往阿司匹林使用者未见此关联。
  • 抗凝前使用阿司匹林未改变同期治疗与新发心肌梗死或卒中的关系,抗凝前停用阿司匹林未使这些事件率增加。
  • 作者认为需进一步研究以明确外科患者抗凝期间抗血小板治疗的最佳管理。

适用人群与场景

  • 成人(≥18岁)在术后ICU住院期间接受抗凝治疗的患者,来自学术医疗中心术后ICU,时间范围为2007至2016年。

研究设计与关键结果

  • 逆概率治疗加权分析中,同期治疗与主要出血风险增加相关(OR 1.20;95%CI 1.05-1.36;P=0.006),对照为单用抗凝治疗。
  • 交互检验提示阿司匹林与主要出血的关系因抗凝前7天内是否使用阿司匹林而异:近期新起始阿司匹林者OR 1.40(95%CI 1.13-1.72;P=0.002),继续既往阿司匹林使用者未见此关联。
  • 抗凝前使用阿司匹林未改变同期治疗与新发心肌梗死或卒中的关系(即抗凝前停用阿司匹林未使这些事件率增加)。

证据类型、等级与局限

  • 证据类型:观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,术后ICU接受抗凝治疗的外科患者同期使用阿司匹林与主要出血率增加相关。
  • 作者认为,需进一步研究以明确外科患者抗凝期间抗血小板治疗的最佳管理。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
  • 另有 1 条提炼内容因数值无法与原文逐一核对而未列出,请以原文为准。
英文原文(摘要)· 点击展开

OBJECTIVES: Critically ill surgical patients may receive concomitant aspirin and therapeutic anticoagulation postoperatively, yet the safety of this practice remains unknown. We evaluated the risk of major bleeding with concomitant therapy compared with anticoagulation alone.

DESIGN: Observational cohort study. Inverse probability of treatment weighting was used to assess the association between concomitant therapy and a primary outcome of major bleeding.

SETTING: Postoperative ICUs at an academic medical center.

PATIENTS: Adults (≥ 18 yr old) receiving anticoagulation during postoperative ICU admission between 2007 and 2016.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Nine thousand five hundred eighteen anticoagulated patients were included, including 3,237 (34%) receiving aspirin. A total of 1,874 unique patients (19.7%) experienced a major bleeding event. In inverse probability of treatment weighting analyses, concomitant therapy was associated with increased odds for major bleeding (odds ratio, 1.20; 95% CI, 1.05-1.36; p = 0.006) compared with anticoagulation alone. An interaction test suggested a differential relationship between aspirin use and major bleeding based on aspirin use in the 7 days prior to anticoagulation, such that a strong association between aspirin and major bleeding was observed for recent initiators of aspirin (1.40; 1.13-1.72;p = 0.002) but not for those continuing prior aspirin use. Aspirin use prior to anticoagulation did not modify the relationship between concomitant therapy and new myocardial infarction or stroke (i.e., rates were not increased with aspirin discontinuation prior to anticoagulation).

CONCLUSIONS: Concomitant aspirin and anticoagulation in critically ill surgical patients was associated with an increased rate of major bleeding. Future investigations are warranted to further define optimal management of antiplatelet therapy during anticoagulation in surgical patients.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Rayes HA, Subat YW, Weister T, et al. Concomitant Aspirin and Anticoagulation Is Associated With Increased Risk for Major Bleeding in Surgical Patients Requiring Postoperative Intensive Care. Crit Care Med. 2020. PMID: 32304413. doi:10.1097/CCM.0000000000004350

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。